149 related articles for article (PubMed ID: 31479592)
1. Identification of a thermal degradation product of CUMYL-PEGACLONE and its detection in biological samples.
Nash C; Glowacki L; Gerostamoulos D; Pigou P; Scott T; Kostakis C
Drug Test Anal; 2019 Oct; 11(10):1480-1485. PubMed ID: 31479592
[TBL] [Abstract][Full Text] [Related]
2. Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples.
Mogler L; Wilde M; Huppertz LM; Weinfurtner G; Franz F; Auwärter V
Drug Test Anal; 2018 May; 10(5):886-891. PubMed ID: 29314750
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Cumyl-PEGACLONE-related fatalities in the Northern Territory of Australia.
Tiemensma M; Rutherford JD; Scott T; Karch S
Forensic Sci Med Pathol; 2021 Mar; 17(1):3-9. PubMed ID: 33185835
[TBL] [Abstract][Full Text] [Related]
4. Testing for SGT-151 (CUMYL-PEGACLONE) and its Metabolites in Blood and Urine after Surreptitious Administration.
Aknouche F; Ameline A; Richeval C; Schapira AJ; Coulon A; Maruejouls C; Gaulier JM; Kintz P
J Anal Toxicol; 2020 Jan; 44(1):75-80. PubMed ID: 30877795
[TBL] [Abstract][Full Text] [Related]
5. Detection of Synthetic Cannabinoid CUMYL-PEGACLONE in E-Cigarette Oil and Hair.
Jiao TF; Li YQ; Kang G; Chen SS; Cheng LH
Fa Yi Xue Za Zhi; 2022 Oct; 38(5):595-600. PubMed ID: 36727175
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity profiling of Cumyl-PEGACLONE variants at the CB
Janssens L; Cannaert A; Connolly MJ; Liu H; Stove CP
Drug Test Anal; 2020 Sep; 12(9):1336-1343. PubMed ID: 32490586
[TBL] [Abstract][Full Text] [Related]
7. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in summer 2018.
Ernst L; Langer N; Bockelmann A; Salkhordeh E; Beuerle T
Forensic Sci Int; 2019 Jan; 294():96-102. PubMed ID: 30497049
[TBL] [Abstract][Full Text] [Related]
8. The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a γ-Carboline-1-One Core.
Haschimi B; Giorgetti A; Mogler L; Nagy TZ; Kramer S; Halter S; Boros S; Dobos A; Hidvégi E; Auwärter V
J Anal Toxicol; 2021 Mar; 45(3):277-290. PubMed ID: 32514544
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Herbal Mixtures Containing Cumyl-PEGACLONE-Is Inhomogeneity Still an Issue?
Halter S; Mogler L; Auwärter V
J Anal Toxicol; 2020 Jan; 44(1):81-85. PubMed ID: 31044247
[TBL] [Abstract][Full Text] [Related]
10. Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE.
Mogler L; Halter S; Wilde M; Franz F; Auwärter V
Forensic Toxicol; 2019; 37(1):154-163. PubMed ID: 30636984
[TBL] [Abstract][Full Text] [Related]
11. Detection of metabolites of the new synthetic cannabinoid CUMYL-4CN-BINACA in authentic urine samples and human liver microsomes using high-resolution mass spectrometry.
Öztürk YE; Yeter O; Öztürk S; Karakus G; Ates I; Buyuk Y; Yurdun T
Drug Test Anal; 2018 Mar; 10(3):449-459. PubMed ID: 28691766
[TBL] [Abstract][Full Text] [Related]
12. Cardiac effects of 5F-Cumyl-PEGACLONE.
Esdar N; Pawlik E; Eickhoff SB; Raupach A; Ritz-Timme S; Mayer F
Int J Legal Med; 2024 May; 138(3):823-831. PubMed ID: 38214738
[TBL] [Abstract][Full Text] [Related]
13. Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?
Halter S; Angerer V; Röhrich J; Groth O; Roider G; Hermanns-Clausen M; Auwärter V
Drug Test Anal; 2019 Feb; 11(2):347-349. PubMed ID: 30468574
[No Abstract] [Full Text] [Related]
14. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE.
Angerer V; Mogler L; Steitz JP; Bisel P; Hess C; Schoeder CT; Müller CE; Huppertz LM; Westphal F; Schäper J; Auwärter V
Drug Test Anal; 2018 Mar; 10(3):597-603. PubMed ID: 28670781
[TBL] [Abstract][Full Text] [Related]
15. Identification of urinary metabolites of the synthetic cannabinoid 5F-CUMYL-P7AICA in human casework.
Staeheli SN; Steuer AE; Kraemer T
Forensic Sci Int; 2019 Jan; 294():76-79. PubMed ID: 30471536
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018.
Ong RS; Kappatos DC; Russell SGG; Poulsen HA; Banister SD; Gerona RR; Glass M; Johnson CS; McCarthy MJ
Drug Test Anal; 2020 Feb; 12(2):195-214. PubMed ID: 31595682
[TBL] [Abstract][Full Text] [Related]
17. Identification of the Synthetic Cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in Plant Material and Quantification in Post-Mortem Blood Samples.
Yeter O
J Anal Toxicol; 2017 Nov; 41(9):720-728. PubMed ID: 28977413
[TBL] [Abstract][Full Text] [Related]
18. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017.
Ernst L; Brandhorst K; Papke U; Altrogge A; Zodel S; Langer N; Beuerle T
Forensic Sci Int; 2017 Aug; 277():51-58. PubMed ID: 28601726
[TBL] [Abstract][Full Text] [Related]
19. A rapid quantitative method for the analysis of synthetic cannabinoids by liquid chromatography-tandem mass spectrometry.
Freijo TD; Harris SE; Kala SV
J Anal Toxicol; 2014 Oct; 38(8):466-78. PubMed ID: 25217534
[TBL] [Abstract][Full Text] [Related]
20. Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluation.
Giorgetti A; Mogler L; Haschimi B; Halter S; Franz F; Westphal F; Fischmann S; Riedel J; Pütz M; Auwärter V
Drug Test Anal; 2020 Jan; 12(1):78-91. PubMed ID: 31476105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
